Hormonal
GLP-1 receptor agonists may improve psoriasis symptoms (PASI score) in patients with Type 2 Diabetes, though evidence from randomized controlled trials is mixed.
If you have psoriasis and Type 2 Diabetes, GLP-1 medications might help improve your skin symptoms, but this is not guaranteed. The most reliable benefit is the protection against heart disease and stroke. Discuss with your doctor if the potential skin benefits, combined with cardiovascular protection, outweigh the need for an injection.
The majority of case reports and prospective cohort studies found GLP-1RAs improved psoriasis, while two randomized controlled trials showed conflicting results.
Why this rating
Based on case reports, cohort studies, and conflicting small RCTs; larger studies needed.
Source
Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
Kathryn Haran et al. · Psoriasis Targets and Therapy · 2024
DOI 10.2147/ptt.s485061
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →